• Türkçe
    • English
  • English 
    • Türkçe
    • English
  • Login
View Item 
  •   DSpace Home
  • Eczacılık Fakültesi
  • Temel Eczacılık Bilimleri Bölümü
  • Temel Eczacılık Bilimleri Bölümü Tez Koleksiyonu
  • View Item
  •   DSpace Home
  • Eczacılık Fakültesi
  • Temel Eczacılık Bilimleri Bölümü
  • Temel Eczacılık Bilimleri Bölümü Tez Koleksiyonu
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Raloksifen'in Biyolojik Materyalden ve Farmasötik Preparattan Analizi İçin Gaz Kromatografisi-Kütle Spektrometrisi Yönteminin Geliştirilmesi ve Valide Edilmesi

Thumbnail
View/Open
8c5fd4da-52e2-48dd-8352-4ee63f5ada0d.pdf (2.807Mb)
Date
2012
Author
Tandoğan, Münevver
xmlui.mirage2.itemSummaryView.MetaData
Show full item record
Abstract
Raloxifene is selective estrogen modulator (SERM) drug which is used in the treatment of postmenopausal osteoporosis in women and used for doping in men. A new gas chromatography-mass spectrometry (GC-MS) method was developed for the determination of Raloxifene in human urine and pharmaceutical preparation. Raloxifene was silylated prior to GC-MS analysis. Derivatization reaction was optimized to investigate parameters such as different derivatization reagents, reaction temperatures and times. It was efficiently derivatized using MSTFA/ß-mercaptoethanol/NH4I at 80 °C for 30 min. Methyltestosterone was selected as internal Standard (IS). Analysis was performed in selected ion monitoring (SIM) mode. The ions m/z 578 for raloxifene and m/z 446 for IS were selected for quantitation. Chromatographic variables (initial and final oven temperature, flow rate of gas) were investigated to optimize the chromatographic method. Raloxifene was extracted from urine with carbonate buffer (pH 9.0) and methyl ter-butyl ether. The developed method was validated in terms of system suitability tests, specificity, sensitivity, linearity, accuracy, precision, recovery, stability, robustness and ruggedness for analysis of Raloxifene in each urine and pharmaceutical formulation. Linearity was established in the range of 10-200 ng mL-1, limit of quantification (LOQ) was 10.0 ng mL-1 and limit of detection (LOD) was 8.0 ng mL-1 for urine. Linearity was found 10-400 ng, LOQ was 10.0 ng and LOD was 5.0 ng for pharmaceutical analysis. Developed method was sensitive, precise, accurate, specific, sensitive, rugged and robust due to the validation study results. The developed and validated method was successfully applied to analysis of the pharmaceutical preparation containing raloxifene HCl. The results were compared to the method in literature and no significant difference was found between them.
URI
http://hdl.handle.net/11655/1161
xmlui.mirage2.itemSummaryView.Collections
  • Temel Eczacılık Bilimleri Bölümü Tez Koleksiyonu [41]
Hacettepe Üniversitesi Kütüphaneleri
Açık Erişim Birimi
Beytepe Kütüphanesi | Tel: (90 - 312) 297 6585-117 || Sağlık Bilimleri Kütüphanesi | Tel: (90 - 312) 305 1067
Bizi Takip Edebilirsiniz: Facebook | Twitter | Youtube | Instagram
Web sayfası:www.library.hacettepe.edu.tr | E-posta:openaccess@hacettepe.edu.tr
Sayfanın çıktısını almak için lütfen tıklayınız.
Contact Us | Send Feedback



DSpace software copyright © 2002-2016  DuraSpace
Theme by 
Atmire NV
 

 


DSpace@Hacettepe
huk openaire onayı
by OpenAIRE

About HUAES
Open Access PolicyGuidesSubcriptionsContact

livechat

sherpa/romeo

Browse

All of DSpaceCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsTypeDepartmentPublisherLanguageRightsxmlui.ArtifactBrowser.Navigation.browse_indexFundingxmlui.ArtifactBrowser.Navigation.browse_subtypeThis CollectionBy Issue DateAuthorsTitlesSubjectsTypeDepartmentPublisherLanguageRightsxmlui.ArtifactBrowser.Navigation.browse_indexFundingxmlui.ArtifactBrowser.Navigation.browse_subtype

My Account

LoginRegister

Statistics

View Usage Statistics

DSpace software copyright © 2002-2016  DuraSpace
Theme by 
Atmire NV